Author: Daniel Benker
Stop TB Partnership’s Global Drug Facility and Otsuka announce a new private-public partnership to expand worldwide access to an MDR-TB drug.
Last updated: 2017-05-05 19:22:14
Clinical access programme for an MDR-TB medicine launched in South Africa.
Last updated: 2017-06-15 15:49:19
Efficacy results of Otsuka’s drug for extensively drug-resistant TB (XDR-TB) published in the New England Journal of Medicine.
Last updated: 2017-05-05 19:23:19
The Japanese Ministry of Health, Labour and Welfare approved a medicine developed by Otsuka for treatment of adults with pulmonary MDR-TB.
Last updated: 2017-05-05 19:24:16
Otsuka Wins European Marketing Authorization for a medicine to treat adult pulmonary MDR-TB.
Last updated: 2017-05-05 19:24:52
The Stop TB Partnership announced Otsuka’s new anti-tuberculosis (TB) compound, to be developed as part of a pan-TB regimen.
Last updated: 2017-05-05 19:19:40
The WHO published the new edition of its Model List of Essential Medicines, which includes new treatments for multidrug-resistant (MDR-TB).
Last updated: 2017-05-05 19:20:41
The WHO released an updated companion handbook to the WHO guidelines for the programmatic management of drug-resistant TB.
Last updated: 2017-05-05 19:21:08